ARCT — Arcturus Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $361.52m
- $159.57m
- $152.31m
- 47
- 37
- 61
- 46
Annual cashflow statement for Arcturus Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -72.1 | -204 | 9.35 | -29.7 | -80.9 |
| Depreciation | |||||
| Non-Cash Items | 7.19 | 36.2 | 33.7 | 1.29 | 38.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 21.2 | 31.2 | -12.6 | 7.38 | -20.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -42.9 | -135 | 32 | -18.1 | -59.7 |
| Capital Expenditures | -1.74 | -3.41 | -7.73 | -2.9 | -0.648 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -1.74 | -3.41 | -7.73 | -2.9 | -0.648 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 436 | 48 | -2.86 | -24.1 | 5.42 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 392 | -90.4 | 21.4 | -45.1 | -55 |